Full Press Release Details
V ertex Pharmaceuticals revolutionized the treatment of cystic fibrosis. It also has unfinished business.
The Boston drugmaker’s medicines for the genetic disease — which damages the lungs and other organs — have transformed the lives of patients, helping them abandon other time-consuming treatments, shrug off what would have been dangerous respiratory infections, and just live breathing easier. The drugs, a number of so-called modulators approved starting in 2012, have been one of the great biotech success stories .
Advertisement
But the medications don’t work for some 10% of patients , depending on which CF-causing mutations they inherit. These patients have watched as their peers’ lives have changed, while they remain stuck using old medications to manage their symptoms and to slow the worsening of their illnesses.
STAT+ Exclusive Story
Already have an account? Log in
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.
Already have an account? Log in
Monthly
$39
Totals $468 per year
Totals $468 per year
Starter
$30
for 3 months, then $399/year
Then $399/year
Annual
$399
Save 15%
Save 15%
11+ Users
Custom
Savings start at 25%!
Savings start at 25%!
2-10 Users
$300
Annually per user
$300 Annually per user
To read the rest of this story subscribe to STAT+.
About the Author Reprints
Andrew Joseph
Europe Correspondent
Andrew covers the biopharma industry, scientific research, and public health across the continent. You can reach Andrew confidentially on Signal at drewqjoseph.71.